HARDEN: Constrained Evolutionary Search for Harder, Answer-Preserving Evaluation Cases
Organizations: Distyl AI · Polytechnique Montréal · Mila – Quebec AI Institute
Abstract
Language models are often evaluated on curated benchmarks that underrepresent the complexity of enterprise deployments. We introduce HARDEN, a constrained evolutionary search method to adapt the input of existing evaluation cases into more challenging variants while keeping their expected outputs fixed. HARDEN searches along generated domain-specific complexity axes while enforcing feasibility constraints such as preserving task semantics, realism, and execution validity. Across FinQA, PubMedQA, and ContractNLI and three Qwen3.5 model scales (35B-A3B, 122B-A10B, and 397B-A17B), HARDEN reduces task-model accuracy by 22.7% on average and by up to 49.9% relative to single-pass baselines using the same feasibility checks. These results show that evolutionary search can produce substantially harder valid evaluation cases.
Figures & tables
Appendix figures & tables17 assets
Supplementary material from the paper’s appendix.
Appendix
| ID | Dimension | Operational high-score anchor |
|---|---|---|
| D1 | Tabular numeric density and structure | A genuine financial table, typically with at least eight labeled line items, at least two value columns, and at least 25% numeric cells. |
| D2 | Financial line-item and disclosure vocabulary | At least six distinct financial terms or line items, such as revenue, cost of sales, operating income, total assets, cash flow, or fiscal year. |
| D3 | Authentic accounting numeric formatting | At least three authentic conventions, including thousands separators, parenthesized negatives, currency or scale markers, period headers, percentages, per-share values, or footnote markers. |
| D4 | Grounded numerical-reasoning intent | The question names a metric or period present in the report and requests a computable value, change, difference, ratio, percentage, or aggregate. |
| Axis | Example mutation |
|---|---|
| Table-label compression | Replace verbose row and column descriptions with authentic filer shorthand. |
| Table-lookup ambiguity | Add plausible sibling rows, subtotals, or comparative-period columns. |
| Numeric-format heterogeneity | Mix currency symbols, separators, parenthetical negatives, and dash zeros. |
| Financial-terminology variation | Use standard financial synonyms across the question and source. |
| Narrative-distractor density | Add non-decisive figures and footnote detail from related disclosures. |
| Cross-reference indirection | Route a fact through a resolvable footnote or remove a duplicate restatement. |
| Original | HARDEN |
|---|---|
| MUTUAL NON-DISCLOSURE AGREEMENT Each undersigned party (the “Receiving Party”) understands that… | MUTUAL NON-DISCLOSURE AGREEMENT WITNESSETH: WHEREAS , CombiChem, Inc., a Delaware corporation, and DuPont Pharmaceuticals Company, a Delaware general partnership (each a “party” and collectively the “parties”), are engaged in discussions concerning a possible business transaction of mutual interest; and WHEREAS , in the course of such discussions each party may find it desirable to disclose to the other certain of its proprietary and confidential information…; and WHEREAS , the parties desire to establish the terms and conditions governing the disclosure, protection and use of such information; NOW, THEREFORE , in consideration of the mutual covenants and promises contained herein…, the parties agree as set forth below. Each undersigned party (the “Receiving Party”) understands that… |
| IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year set forth below. Date: 3-10-99 … | IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their respective duly authorized representatives as of the day and year set forth below. Date: 3-10-99 … Address for Notices: CombiChem, Inc., Attn: General Counsel, San Diego, California DuPont Pharmaceuticals Company, Attn: Legal Department, Wilmington, Delaware |
| Benchmark | Task model | Original | Few-Shot | Few-Shot (web-search) | HARDEN |
|---|---|---|---|---|---|
| FinQA | Qwen 3.5 35B | 71.6 | 69.1 (69.8) | 66.3 (68.5) | 49.4 |
| FinQA | Qwen 3.5 122B | 72.4 | 69.5 (71.1) | 69.4 (70.0) | 59.6 |
| FinQA | Qwen 3.5 397B | 73.8 | 72.1 (72.7) | 72.1 (72.3) | 60.5 |
| PubMedQA | Qwen 3.5 35B | 76.1 | 80.6 (80.2) | 81.9 (81.9) | 50.4 |
| PubMedQA | Qwen 3.5 122B | 77.7 | 81.3 (80.7) | 83.4 (83.4) | 33.5 |
| PubMedQA | Qwen 3.5 397B | 76.8 | 82.1 (81.5) | 82.1 (82.0) | 37.9 |
| Benchmark | Task model | Original | Few-Shot | Few-Shot (web-search) | HARDEN |
|---|---|---|---|---|---|
| FinQA | Qwen 3.5 35B | 0.17 | 0.22 (0.20) | 0.26 (0.21) | 0.44 |
| FinQA | Qwen 3.5 122B | 0.14 | 0.15 (0.13) | 0.17 (0.15) | 0.32 |
| FinQA | Qwen 3.5 397B | 0.09 | 0.13 (0.11) | 0.12 (0.10) | 0.22 |
| PubMedQA | Qwen 3.5 35B | 0.16 | 0.11 (0.11) | 0.14 (0.14) | 0.35 |
| PubMedQA | Qwen 3.5 122B | 0.11 | 0.10 (0.10) | 0.10 (0.10) | 0.39 |
| PubMedQA | Qwen 3.5 397B | 0.08 | 0.09 (0.08) | 0.10 (0.10) | 0.32 |
| Benchmark | Task model | Original | Few-Shot | Few-Shot (web-search) | HARDEN |
|---|---|---|---|---|---|
| FinQA | Qwen 3.5 35B | 0.17 | 0.22 (0.20) | 0.26 (0.21) | 0.44 |
| FinQA | Qwen 3.5 122B | 0.13 | 0.15 (0.13) | 0.17 (0.15) | 0.31 |
| FinQA | Qwen 3.5 397B | 0.09 | 0.13 (0.11) | 0.12 (0.10) | 0.22 |
| PubMedQA | Qwen 3.5 35B | 0.15 | 0.11 (0.11) | 0.13 (0.13) | 0.34 |
| PubMedQA | Qwen 3.5 122B | 0.11 | 0.10 (0.10) | 0.10 (0.10) | 0.39 |
| PubMedQA | Qwen 3.5 397B | 0.08 | 0.09 (0.08) | 0.10 (0.10) | 0.32 |
| Benchmark | Task model | Original | Few-Shot | Few-Shot (web-search) | HARDEN |
|---|---|---|---|---|---|
| FinQA | Qwen 3.5 35B | 100.9 | 106.2 (94.0) | 113.8 (92.6) | 140.8 |
| FinQA | Qwen 3.5 122B | 61.8 | 83.5 (66.7) | 78.8 (65.6) | 70.3 |
| FinQA | Qwen 3.5 397B | 22.3 | 20.3 (21.5) | 30.9 (25.7) | 25.1 |
| PubMedQA | Qwen 3.5 35B | 56.7 | 58.8 (58.5) | 66.8 (66.6) | 78.0 |
| PubMedQA | Qwen 3.5 122B | 48.1 | 47.1 (47.0) | 52.3 (52.1) | 56.6 |
| PubMedQA | Qwen 3.5 397B | 16.7 | 19.8 (19.4) | 24.2 (24.2) | 23.5 |
| Benchmark | Task model | Original | Few-Shot | Few-Shot (web-search) | HARDEN |
|---|---|---|---|---|---|
| FinQA | Qwen 3.5 35B | 0.101 | 0.103 (0.101) | 0.097 (0.096) | 0.111 |
| FinQA | Qwen 3.5 122B | 0.076 | 0.080 (0.078) | 0.075 (0.072) | 0.081 |
| FinQA | Qwen 3.5 397B | 0.032 | 0.027 (0.029) | 0.032 (0.031) | 0.034 |
| PubMedQA | Qwen 3.5 35B | 0.210 | 0.210 (0.209) | 0.212 (0.212) | 0.227 |
| PubMedQA | Qwen 3.5 122B | 0.150 | 0.149 (0.149) | 0.146 (0.146) | 0.167 |
| PubMedQA | Qwen 3.5 397B | 0.055 | 0.051 (0.051) | 0.053 (0.053) | 0.059 |
| Benchmark | Task model | Hardened cases | Accuracy (%) | Semantic entropy |
|---|---|---|---|---|
| FinQA | Qwen 3.5 35B | 126 of 200 | ||
| FinQA | Qwen 3.5 122B | 101 of 200 | ||
| FinQA | Qwen 3.5 397B | 61 of 200 | ||
| PubMedQA | Qwen 3.5 35B | 121 of 200 | ||
| PubMedQA | Qwen 3.5 122B | 142 of 200 | ||
| PubMedQA | Qwen 3.5 397B | 122 of 200 |
| Benchmark | Source | Agentic check | Human majority |
|---|---|---|---|
| FinQA | Official | 90% | 60% |
| FinQA | GPT-5.6 Sol | 95% | 70% |
| FinQA | GPT-3.5 Turbo | 0% | 60% |
| PubMedQA | Official | 100% | 95% |
| PubMedQA | GPT-5.6 Sol | 100% | 100% |
| PubMedQA | GPT-3.5 Turbo | 90% | 60% |
| Benchmark | Agreement | Cohen’s | Gwet’s AC1 | Positive agr. | Negative agr. | /MCC |
|---|---|---|---|---|---|---|
| FinQA | 51.7% | 0.090 | 61.3% | 35.6% | ||
| PubMedQA | 85.0% | 0.135 | 0.820 | 91.7% | 18.2% | 0.182 |
| Benchmark | TP/FN/FP/TN | Accuracy | /MCC | Cohen’s | Specificity | McNemar Holm |
|---|---|---|---|---|---|---|
| FinQA | 10/0/9/1 | 55.0% | 0.229 | 0.100 | 10.0% | 0.0039 |
| PubMedQA | 10/0/10/0 | 50.0% | n/a | 0.000 | 0.0% | 0.0039 |
| Benchmark | Manual incorrect | Counterfactual | Label flip | Manual correct |
|---|---|---|---|---|
| FinQA | 5/8 | 5/5 | 5/5 | 3/3 |
| Benchmark | TP/FN/FP/TN | Accuracy (95% CI) | Correct recall | Incorrect specificity |
|---|---|---|---|---|
| FinQA | 3/1/2/15 | 85.7% (65.4–95.0) | 75.0% | 88.2% |
LLM Evaluation
Large language model evaluation measures what models can do, how reliably they do it, and whether benchmark scores predict real-world performance.
See all 2,427 papers